The dysregulation of the JAK-STAT pathway, a key signaling mechanism in CTCL progression, is particularly evident in patients treated with immunomodulatory agents or biologics [6, 7, 9]. The gene discussed is SOAT1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.